touchLearning Activities
Education, Conference Coverage and Articles
Interstitial lung disease (ILD) is a common and potentially fatal complication of systemic autoimmune rheumatic diseases (SARDs), such as rheumatoid arthritis (RA) and systemic sclerosis (SSc). ILD may be the first sign of disease or develop later, often with variable clinical courses. Early detection is critical, as delayed diagnosis contributes to poor outcomes. In response, the 2023 American College of Rheumatology (ACR) guidelines emphasize routine screening and risk-based strategies to improve identification and management of SARD-associated ILD (SARD-ILD).
In this Future Leaders interview, Dr Salvatore Oliva discusses his path to paediatric gastroenterology, highlighting his focus on chronic inflammatory conditions like IBD and EGIDs. He shares insights on leading European collaborative research, the integration of innovation into clinical care, and the promise of precision medicine. Dr Oliva also offers guidance for early-career doctors drawn to this dynamic and multidisciplinary field.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.
As part of our Future Leaders series, we spotlight Dr Sonali Bracken, a physician-scientist at Duke University advancing rheumatologic care through cutting-edge research on B cells in autoimmunity. Recently awarded the 2024 ACR Distinguished Fellow Award, Dr Bracken shares insights into her path, research focus, and the emerging therapies poised to transform patient outcomes.
As part of our coverage of DDW 2025, we speak with Dr Florian Rieder about the STENOVA trial evaluating AGMB-129 in fibrostenosing Crohn’s disease. He discusses the rationale behind targeting the TGF-β pathway, the trial design, and promising interim findings suggesting localized efficacy and improved stricture symptoms without systemic toxicity.
In this interview with Dr. Stuart Silverman, we discuss his WCO-IOF-ESCEO 2025 presentation on the clinical utility of bone turnover markers (BTMs) in osteoporosis care. BTMs such as s-CTX and s-PINP, standardized by the IOF-IFCC, provide insights into bone remodelling, support treatment monitoring, guide therapy adjustments, and help personalize drug holidays, though they complement rather than replace traditional diagnostic tools.
touchREVIEWS in RMD is proud to welcome Dr Vinod Ravindran to our editorial board. With a distinguished background in clinical rheumatology, medical education, and research, Dr Ravindran is widely recognized for his contributions to advancing care and understanding in the field.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Dr. Vinod Ravindran (Centre for Rheumatology, Calicut, Kerala, India) shares his highlights from RheumaPreg 2025, held in Vienna. The conference covered the full spectrum of pregnancy management in autoimmune rheumatic diseases. Here, he reflects on key insights from expert-led sessions on fertility, immunosuppression, lupus care, and postpartum outcomes.
Nominated Future Leader, Dr Tom Appleton, shares insights into his career, osteoarthritis research, and the role of immunology in shaping future OA treatments. In this interview, Dr Appleton discusses the importance of early intervention, the impact of synovial macrophage dysfunction, and emerging therapies that could revolutionize rheumatology. His work bridges clinical care and research to drive innovation in osteoarthritis management and autoimmune disease.
Findings from the Spring Study – CM-101 for Primary Sclerosing Cholangitis: Paul Pockros, DDW 2025
In the interview, Dr Paul Pockros discusses his presentation from DDW 2025 on the SPRING study (NCT04595825), which evaluated CM-101, a novel anti-CCL24 monoclonal antibody, in adults with primary sclerosing cholangitis (PSC). With no FDA-approved treatments for PSC, CM-101 showed promising safety, tolerability, and biomarker improvements over 48 weeks, supporting advancement to phase 3 trials.
Osteoarthritis is increasingly recognised as a heterogeneous disease with diverse clinical phenotypes and molecular endotypes. In this expert Q&A, Professor Ali Mobasheri discusses how precision medicine—through clinical phenotyping and molecular endotyping—can guide targeted therapies, accelerate the development of disease-modifying treatments, and transform OA management into a personalised, proactive approach that improves patient outcomes.
At the 2025 WCO-IOF-ESCEO congress, Professor Philip Conaghan presented the safety and efficacy findings from the phase 2 study of LEVI-04 for the treatment of adults with knee osteoarthritis. LEVI-04 is a first-in-class, NT-3 inhibitor, which works by targeting the inflammatory pathways involved in joint degeneration and selectively inhibiting pro-inflammatory cytokines.
The European Commission has approved upadacitinib for treating giant cell arteritis (GCA) in adults. This marks the first oral JAK inhibitor approved for GCA in the EU. Backed by the findings from the phase III SELECT-GCA trial, upadacitinib offers a new option for managing this chronic inflammatory disease in adults.
In this edition of our Future Leaders series, we speak with Dr. Santhanam Sham, a rising star in rheumatology. As a Senior Consultant at Kauvery Hospitals, Chennai, Dr. Sham is dedicated to advancing research on autoimmune diseases like SLE and vasculitis, while also fostering patient-centric care and embracing cutting-edge medical technologies.
The IMPACT-PLuS long-term follow-up trial found that children who underwent peanut oral immunotherapy in the earlier IMPACT trial maintained significant changes in their allergen-specific IgE and IgG4 profiles, which could have positive implications for long-term allergy management.
With a career that spans continents, Prof. Dedee Murrell stands out as a global leader in dermatology and a passionate advocate for women in medicine. In this episode, we sit down together to explore her inspiring journey—from her early years in the UK and medical training in the USA to pioneering therapies for some of dermatology’s rarest and underserved conditions in Australia. We also reflect on her recent MDS Lifetime Achievement Award and discuss the value of mentorship, strategies for advancing a career in dermatology and academic medicine, and how to stay at the cutting edge of medical innovation.
touchIMMUNOLOGY
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
